NOTA-FAPI

NOTA-FAPI is a fibroblast activation protein (FAP) inhibitor. NOTA-FAPI can be used as a probe for FAP-targeted tumour imaging. NOTA-FAPI has good tumour detection efficacy and excellent imaging quality[1][2][3].

Product Specifications

CAS Number

[2374782-03-1]

UNSPSC

12352005

Target

FAP; Radionuclide-Drug Conjugates (RDCs)

Type

Reference compound

Related Pathways

Antibody-drug Conjugate/ADC Related; Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/nota-fapi.html

Purity

99.66

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(C1=CC=NC(C=C2)=C1C=C2OCCCN(CC3)CCN3C(CN(CCN4CC(O)=O)CCN(CC4)CC(O)=O)=O)NCC(N(CC5(F)F)[C@@H](C5)C#N)=O

Molecular Formula

C36H47F2N9O8

Molecular Weight

771.81

References & Citations

[1]Wang S, et al. Clinical translational evaluation of Al18F-NOTA-FAPI for fibroblast activation protein-targeted tumour imaging. Eur J Nucl Med Mol Imaging. 2021 Dec;48 (13) :4259-4271. |[2]Guo YH, et al. Comparison of 18F-AlF-NOTA-FAPI and 18F-FDG Imaging in a Patient With Gastric Signet-Ring Cell Carcinoma. Clin Nucl Med. 2021 Nov 1;46 (11) :929-930.|[3]Ge L, et al. Preclinical evaluation and pilot clinical study of [18F]AlF-NOTA-FAPI-04 for PET imaging of rheumatoid arthritis. Eur J Nucl Med Mol Imaging. 2022 Oct;49 (12) :4025-4036.|[4]Guo YH, et al. Comparison of 18F-AlF-NOTA-FAPI and 18F-FDG Imaging in a Patient With Gastric Signet-Ring Cell Carcinoma. Clin Nucl Med. 2021 Nov 1;46 (11) :929-930.